NLS Opinion and Debate

SwedenBIO recently released our new Swedish Drug Discovery and Development Pipeline Report 2026 at NLSDays in Gothenburg. This fourteenth edition once again shows that Swedish drug development remains on a stable trajectory. Fluctuations in the number of drug-developing companies and in the number or type of projects are minimal compared to our report from three years ago.

Many times in life, as in politics and business, bad events lead to painful change and, eventually, a better situation. While the Trump administration’s erratic tariff war has rattled the European life science industry, it might ultimately be the calamity that brings about a more resilient industry in the end.

One of the most compelling trends in the life science sector today is the evolving role of data in decision-making processes. Life science companies are harnessing big data in ways that were once unimaginable, driven by technological advancements like AI, machine learning, and digital transformation. But as we look beyond 2025, it’s crucial to ask: How can these vast data resources be used to create actionable insights that lead to real-world impact? 

If we look at the existing life science hot spots mentioned in the Draghi report, including Medicon Valley, it is obvious that the likelihood of success will increase dramatically, if we embrace the Golden Triangle in the UK (London- Oxford-Cambridge).

Innovation is obviously a key component of future competitiveness. Consequently, the very same stakeholders from industry, academia, research and the political sphere, who have embraced the Draghi report’s recommendations on European competitiveness and the European life science strategy published this summer by the European Commission, have also welcomed the new 2025 European Innovation Scoreboard analysis.

Although the Danish-Swedish life science cluster organization Medicon Valley Alliance was established way back in 1997, the true momentum for Medicon Valley, essentially the EU’s leading life science cluster, started with a kiss.

Norway can deliver on the EU’s ambitious life science strategy and contribute to health preparedness by building national capacity for RNA formulation and scale-up. 

When the next pandemic, climate-driven health crisis, or antimicrobial threat strikes will we be ready? True preparedness is not measured in stockpiles or contingency plans alone. It lies in our ability to harness life science as a cornerstone of resilience – connecting human, animal, and environmental health to build societies that can withstand the crises of tomorrow.

Reflections from the 6th Norwegian Life Science Investor Partnering Day.

The Finnish economy has had difficulties achieving robust growth following the financial crisis. The number of startups in the life science sector is declining and existing companies are struggling to secure funding.

The competitiveness of the EU is waning. In his speech in Berlin on May 22, 2023 the Belgian Prime Minister Alexander De Croo said, “The question ahead of us is: how do we continue to grow our European industry? The answer is: with a European Industrial Deal at the same level of a European Green […]

In good times, when things are rolling along seamlessly, it’s easy to forget that we genuinely need others to prosper. It’s simple to believe that success or failure solely lies in our hands. This applies to our personal lives, companies, and even on a national level. When the ride becomes bumpy and challenging times unfold, […]